Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 274
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 27 Jan 2024 Results of an analysis employed mixture cure models assessing underlying cure fraction among high-risk MIUC patients following radical resection in this trial presented at the 2024 Genitourinary Cancers Symposium
    • 17 Jan 2024 According to a Bristol-Myers Squibb media release, analyses of disease-free survival from this study will be presented in a late-breaking oral presentation at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.
    • 02 Jan 2024 Planned End Date changed from 15 May 2027 to 27 May 2027.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top